Abstract
Purpose :
To evaluate real world visual outcomes and subretinal fluid (SRF) in patients with Pachychoroid features and Type 1 CNV(choroidal neovascularisation) treated with antiVEGF (Vascular Endothelial Growth Factor)
Methods :
Retrospective analysis of 17 eyes of 17 patients with Type 1 CNV and at least 1 pachychoroid feature/chronic Central Serous Chorioretinopathy (CSR), confirmed using OCT, FFA, ICG and OCTA. All patients had treatment with antiVEGF. Snellen BCVA (best corrected visual acuity) at presentation and at the final follow up visit were compared.; as well as presence of subretinal fluid.
Results :
Mean age of patients was 73.7 years (57-84 years) with a mean follow up period of 39.6 months (range 12- 107 months). Mean number of antiVEGF injections was 18.1 (2-75).
There was no change in BCVA at presentation and at the final follow up visit in 9/17 (52.9%) patients; 4/17 (23.5%) had improvement in final BCVA by 1-2 lines; while 4/17 (23.5%) worsened by 1-2 lines. All but 1 patient had persistent SRF at the final visit.
Conclusions :
Patients with pachychoroid features/chronic CSR who develop Type 1 CNV may be more resistant to SRF resolution with antiVEGF treatment. However most maintained/improved in their final BCVA despite persistant/fluctuating SRF during the course of treatment.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.